Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Guillermo Garcia-Manero, David Sallman, Stefano R Tarantolo, Amit Verma, Stefanie Groepper, Alice Mims, Yasmin Abaza, James P. Dugan, Valle Gomez G De Soria, Gaurav S Choudhary, Maureen Lane, Wanying Zhao, Ashish Jain, Cole Gallagher, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2024-208292

Published: 2024

Journal Articles

Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Blood (2024) 144 (Supplement 1): 4869.

https://doi.org/10.1182/blood-2024-206887

Published: 2024

Journal Articles

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Gonzalo Maortua Langdon, Raquel De Paz, Pilar Giraldo, Blanca Xicoy, Joaquin Martinez Lopez, Guiomar Bautista Carrascosa, Jose Maria Alonso Alonso, Maria Soledad Noya Pereira, Magdalena Sierra Pacho, Raul Perez Lopez, Silvana Daniela Saavedra Gerosa, Valle Gomez G De Soria, Natalia De Las Heras, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 6604.

https://doi.org/10.1182/blood-2024-208460

Published: 2024

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Long-Term Follow-up of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: A Single-Center Experience

Cristina García Herce, Valle Gómez García de Soria, Alejandro Alonso, Samantha Feijóo, Ana García-Noblejas, Javier Loscertales, Angela Figuera, Juan Luis Steegmann

Blood (2022) 140 (Supplement 1): 12215–12216.

https://doi.org/10.1182/blood-2022-159800

Published: 2022

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

María Díez Campelo, MD PhD, Julio Davila, MD, Sanchez Barba Mercedes, MD, Maria Lopez-Pavia, MD, Esperanza Such, PhD, Teresa Bernal, MD, Elisa Luño, Fernando Ramos, Marisa Calabuig, MD, Helena Pomares, MD, Bernardo Gonzalez, Brayan Merchan, MD, Edgardo Barranco, MD, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, MD, Ana I Vicente, PhD, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, MD, Jose Falantes, MD, Maria Jesus Arilla, Abelardo Bárez, MD, Regina Garcia, MD, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, MD, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, MD PhD, Luis Benlloch, Guillermo Sanz, MD PhD, María Consuelo Cañizo, MD PhD

Blood (2015) 126 (23): 2896.

https://doi.org/10.1182/blood.V126.23.2896.2896

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center

Yizel Elena Paz Nuñez, Beatriz Aguado Bueno, Isabel vicuña Andrés, Ángela Figuera Álvarez, Miriam González-Pardo, Rafael de la Cámara Llanzá, Valle Gómez García de Soria, Reyes Arranz Sáez, MD, Alvaro Arriero García, Elena Jiménez Barral, Susie Veramendi Zavala, Adrian Alegre

Blood (2015) 126 (23): 5536.

https://doi.org/10.1182/blood.V126.23.5536.5536

Published: 2015

Journal Articles

The Role of CMV Serostatus of the Donor in the Graft Lymphoid Composition and Prediction of Gvhd and CMV Reactivation

Anna Kreutzman, PhD, Itxaso Portero Sainz, MSc, Valle Gomez Garcia De Soria, MD PhD, Carlos Fernandez, MD, Royg Mercedes, MD, Ana Marcos, MSc, Beatriz Colom Fernandez, MSc, Ana Ramirez, Laura Cardeñoso, MD PhD, Rafael De La Camara, MD, Cecilia Muñoz Calleja, MD PhD

Blood (2014) 124 (21): 2422.

https://doi.org/10.1182/blood.V124.21.2422.2422

Published: 2014

Journal Articles

CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd

Itxaso Portero, Valle Gomez, MD, Carlos Arandojo, MD, Anna Kreutzman, PhD, Mercedes Royg, MD, Ana Ramirez, Ana Marcos, MSc, Rafael De La Camara, MD, Cecilia Muñoz, MD PhD

Blood (2014) 124 (21): 3930.

https://doi.org/10.1182/blood.V124.21.3930.3930

Published: 2014

Journal Articles

Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)

Blood (2012) 120 (21): 702.

https://doi.org/10.1182/blood.V120.21.702.702

Published: 2012

Journal Articles

Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)

Patricia Font, PhD, Valle Gomez Garcia De Soria, PhD, Javier Loscertales, PhD, Julio Garcia Suarez, PhD, Marta Callejas, PhD, Carmen Burgaleta, PhD, Santiago Osorio, PhD, Carlos Soto, PhD, Lucia Villalon, PhD, Jose Diez-Martin, Ana Villegas, PhD

Blood (2010) 116 (21): 4973.

https://doi.org/10.1182/blood.V116.21.4973.4973

Published: 2010

Journal Articles

A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia.

Blood (2009) 114 (22): 1750.

https://doi.org/10.1182/blood.V114.22.1750.1750

Published: 2009

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts.

Blood (2009) 114 (22): 290.

https://doi.org/10.1182/blood.V114.22.290.290

Published: 2009

Journal Articles

Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

Blood (2008) 112 (11): 640.

https://doi.org/10.1182/blood.V112.11.640.640

Published: 2008

NARROW

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Long-Term Follow-up of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: A Single-Center Experience

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center

The Role of CMV Serostatus of the Donor in the Graft Lymphoid Composition and Prediction of Gvhd and CMV Reactivation

CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd

Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)

Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)

A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia.

Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts.

Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only